Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences

Michael Horowitz MBBS, PhD1 | Vanita R. Aroda MD2 | Jenny Han MS3 | Elise Hardy MD4 | Chris K. Rayner MBBS, PhD1

1Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia
2Community Clinical Research Center, MedStar Health Research Institute, Hyattsville, Maryland
3Pharmapace, San Diego, California
4Clinical Research, AstraZeneca, Gaithersburg, Maryland

Aims: To characterize gastrointestinal adverse events (AEs) with different glucagon-like peptide-1 receptor agonists (GLP-1RAs).

Methods: Two retrospective intention-to-treat analyses of 6-month patient-level data were conducted. Data from three studies comparing exenatide once weekly (n = 617) with exenatide twice daily (n = 606) were pooled, and one (DURATION-6) comparing exenatide once weekly (n = 461) with liraglutide (n = 450) was analysed separately. Patient-reported gastrointestinal AEs were classified as upper or lower, AE incidences and timing were determined, subgroups were analysed, and associations of gastrointestinal AEs with efficacy were examined.

Results: Nausea was the most common gastrointestinal AE for all treatments. Fewer exenatide once-weekly-treated vs exenatide twice-daily- or liraglutide-treated patients reported gastrointestinal AEs (34% vs 45% and 25% vs 41%, respectively; both \( P < .0001 \)). Fewer exenatide once-weekly-treated patients reported upper plus lower events than liraglutide-treated patients \( (P < .001) \); the difference between exenatide once weekly and twice daily was not significant. Within each group, more women than men reported gastrointestinal AEs. Events occurred early and were predominantly mild. Glycated haemoglobin reductions were similar for patients with or without gastrointestinal AEs. Weight loss was greater for patients with gastrointestinal AEs with exenatide once weekly and exenatide twice daily \( (P < .05) \); no difference was observed in DURATION-6.

Conclusions: Gastrointestinal AEs were less frequent with exenatide once weekly vs exenatide twice daily or liraglutide-treated patients reported gastrointestinal AEs (34% vs 45% and 25% vs 41%, respectively; both \( P < .0001 \)). Fewer exenatide once-weekly-treated patients reported upper plus lower events than liraglutide-treated patients \( (P < .001) \); the difference between exenatide once weekly and twice daily was not significant. Within each group, more women than men reported gastrointestinal AEs. Events occurred early and were predominantly mild. Glycated haemoglobin reductions were similar for patients with or without gastrointestinal AEs. Weight loss was greater for patients with gastrointestinal AEs with exenatide once weekly and exenatide twice daily \( (P < .05) \); no difference was observed in DURATION-6.

KEYWORDS
adverse events, exenatide, gastrointestinal disorders, GLP-1 receptor agonists, liraglutide, type 2 diabetes

1 INTRODUCTION

In patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonists (GLP-1RAs) lead to significant reductions in glycated haemoglobin (HbA1c) levels and body weight, and are now approved and used across the spectrum of T2D therapies, as an adjunct to diet and exercise, oral agents or insulin.1 GLP-1RAs are associated with gastrointestinal adverse events (AEs), predominantly nausea, vomiting and diarrhoea. They act by stimulating insulin release and suppressing glucagon secretion in a glucose-dependent fashion, while increasing
Differences between individual GLP-1RAs have been observed regarding the type and frequency of gastrointestinal events, which may be related to the specific agent and/or to pharmacokinetic differences. It is now understood that with short-acting GLP-1RAs, such as exenatide twice daily and lixisenatide, postprandial glucose reduction is associated with substantial slowing of gastric emptying, whereas the slowing of gastric emptying is much less pronounced with longer-acting GLP-1RAs, such as liraglutide and exenatide once weekly. Similar incidence rates for nausea, vomiting and diarrhoea have been reported among patients receiving exenatide twice daily and liraglutide once daily, although nausea was less persistent with liraglutide compared with exenatide twice daily, whereas lower incidences have been reported with exenatide once weekly. More information is needed, however, on the specific gastrointestinal effects of different GLP-1RAs, including broader categories of gastrointestinal symptoms and the possibility that multiple symptoms occur concurrently, and on comparisons between individual GLP-1RAs. Furthermore, patient subgroups that may be at greater risk of gastrointestinal AEs have not been defined, and the implications of these events for glycaemic control and weight loss with different GLP-1RAs have not been explored in large patient populations.

The present analysis characterized gastrointestinal AEs associated with GLP-1RAs using systematically collected clinical trial data from the exenatide once-weekly development programme, including the frequencies and co-incidence of gastrointestinal AEs in patients and subgroups of patients with T2D treated with exenatide once weekly, exenatide twice daily or liraglutide. The potential impact of gastrointestinal AEs on treatment effects, including reductions in HbA1c and weight, was also investigated.

2 | MATERIALS AND METHODS

This was a post hoc analysis of individual patient data from studies in the exenatide once-weekly development programme, with 6-month safety data in which exenatide once weekly was compared directly with another GLP-1RA.

Two analyses of patient-level data were performed: a pooled analysis of three studies comparing exenatide once weekly with exenatide twice daily (DURATION-1, DURATION-5 and NCT00917267), and a separate analysis of the DURATION-6 study, which compared exenatide once weekly and liraglutide.

The designs, inclusion and exclusion criteria, and primary findings of these studies have been reported elsewhere. All studies were randomized, multicentre, open-label trials designed to evaluate glycaemic control over treatment periods ranging from 24 to 30 weeks (Table S1, Supporting Information). Typical titration schedules were followed for exenatide twice daily and liraglutide, with no titration required for exenatide once weekly (Table S1, Supporting Information). Final doses of study medication were exenatide once weekly 2 mg, exenatide twice daily 10 μg and liraglutide once daily 1.8 mg.

2.1 | Recording of gastrointestinal AEs

The data comprised spontaneous, patient-reported gastrointestinal AEs recorded at study visits. The nature and severity of AEs described by patients were recorded by the investigator and were not adjudicated or assessed for severity according to any systematic rating scale. Gastrointestinal AEs were classified according to the Medical Dictionary for Regulatory Activities (MedDRA) terms.

Because investigators were not instructed as to how to define gastrointestinal AE terms, terms other than nausea, vomiting and diarrhoea were included. A list of all reported gastrointestinal AE terms, which did not specify treatment assignment, was reviewed by a gastroenterologist (C.K.R.). Oral events and those with known causes (eg, structural or infectious disorders) were excluded (Table S2, Supporting Information). Gastrointestinal AEs of interest (Table S2, Supporting Information) were then categorized anatomically as upper or lower, with review and consensus by all authors. A patient was categorized as having an "upper" or "lower" AE when only upper or lower gastrointestinal AEs, respectively, were reported and as having "upper + lower" gastrointestinal AEs when at least one upper and one lower gastrointestinal AE was reported either concurrently or at different times.

The intensity of gastrointestinal AEs was categorized as mild, moderate or severe, according to standard definitions, and standard criteria were used to identify serious AEs (Table S3, Supporting Information); patients could be included in up to three severity categories if they had ≥2 events of different intensity. Gastrointestinal AEs withdrawal rates were determined for each treatment, and specific AEs leading to discontinuation were recorded.

2.2 | Analysis of patient subgroups

Patient subgroups were defined according to characteristics that could potentially influence the incidence of gastrointestinal AEs (sex, race/ethnicity [Asian/Hispanic/white], background metformin [use/non-use]) or response to therapy (occurrence or absence of gastrointestinal AEs of interest).

2.3 | Event timing

The timing of specific gastrointestinal AEs was studied with reference to treatment initiation (days on therapy) when an individual event was studied. The proportion of patients with an AE was calculated using the number of patients remaining in the study at each time interval as the denominator. When the timing of multiple gastrointestinal AEs was studied, one was defined as the reference event and the timing of other events was calculated as days before or after the first occurrence of this event.

2.4 | Statistical analyses

All analyses were conducted for the intention-to-treat populations of the included studies, defined as all randomized patients who had taken ≥1 dose of study drug. Only gastrointestinal AEs with onset or worsening after the first randomized study medication dose were analysed. For the purpose of integration, all AEs were re-coded using MedDRA version 16.0.
Incidences of various categories of gastrointestinal AEs were determined in terms of patient numbers, and percentages were calculated from the total size of the appropriate treatment population. Proportions of patients with specific gastrointestinal AEs were compared between treatments using Fisher’s exact test, and two-sided \( P \) values at the \( \alpha \) levels of .05, .001 and .0001 are reported.

Baseline characteristics were calculated descriptively as mean ± standard deviation (s.d.). Changes in HbA1c and body weight were calculated as mean change ± standard error (s.e.) in the defined patient subpopulation. Changes from baseline in HbA1c and weight inferred using the last observation carried forward method. Within-group comparisons of HbA1c and body weight were conducted using a paired t-test, while between-group comparisons were made using Student’s t-test; both reported two-sided \( P \) values at the \( \alpha \) level of .05.

Subgroups with <30 patients were considered to be of insufficient size for statistical analysis.

3 | RESULTS

3.1 | Study population

The pooled analysis population included 1223 patients (exenatide once weekly, \( n = 617 \); exenatide twice daily, \( n = 606 \)) and the DURATION-6 analysis included 911 patients (exenatide once weekly, \( n = 461 \); liraglutide, \( n = 450 \)).

Patient characteristics in the two populations were generally similar; however, the pooled analysis included a greater proportion of Asian patients (56% vs 12%) and a smaller proportion of white patients (31% vs 65%) than DURATION-6, and patients in the pooled analysis had numerically lower mean body weight and body mass index (Table 1).

### TABLE 1  Baseline patient characteristics for pooled analysis and DURATION-6

|                | Pooled analysis\(^1\) (\( n = 1223 \)) | DURATION-6 (\( n = 911 \)) |
|----------------|-----------------------------------------|--------------------------|
|                | Exenatide once weekly (\( n = 617 \))  | Exenatide twice daily (\( n = 606 \)) | Exenatide once weekly (\( n = 461 \)) | Liraglutide (\( n = 450 \)) |
| Age, years     | 55 ± 11                                 | 56 ± 10                  | 56 ± 9                                  | 56 ± 10                  |
| Men, n (%)     | 342 (55)                                | 326 (54)                 | 254 (55)                                | 245 (54)                 |
| Race/ethnicity, n (%) |
| White          | 204 (33)                                | 173 (29)                 | 304 (66)                                | 287 (64)                 |
| Asian          | 345 (56)                                | 344 (57)                 | 55 (12)                                 | 56 (12)                  |
| Hispanic       | 53 (9)                                  | 61 (10)                  | 98 (21)                                 | 99 (22)                  |
| Black          | 15 (2)                                  | 28 (5)                   | 3 (1)                                   | 3 (1)                    |
| Other          | 0                                       | 0                        | 1 (<1)                                  | 4 (1)                    |
| Body weight, kg| 83 ± 22                                  | 83 ± 21                  | 91 ± 19                                 | 91 ± 19                  |
| BMI, kg/m\(^2\)| 30 ± 6                                  | 30 ± 6                   | 32 ± 6                                  | 32 ± 5                   |
| HbA1c, %       | 8.5 ± 1.1                               | 8.5 ± 1.1                | 8.4 ± 1.0                               | 8.4 ± 1.0                |
| FPG, mmol/L    | 9.2 ± 2.5                               | 9.2 ± 2.6                | 9.6 ± 2.5                               | 9.8 ± 2.6                |
| Duration of T2D, years | 7 ± 5                                   | 8 ± 6                    | 8 ± 6                                   | 9 ± 6                    |
| Background metformin, n (%)\(^2\)| 506 (82)                                | 484 (80)                 | 436 (95)                                | 425 (94)                 |

Values are reported as mean ± s.d., unless otherwise stated.

Abbreviations: BMI, body mass index; FPG, fasting plasma glucose.

---

\(^1\) Studies included DURATION-1, DURATION-5 and NCT00917267.

\(^2\) Use of metformin alone or in combination with sulphonylurea, thiazolidinedione, insulin, or other glucose-lowering therapy.
3.3 Patient subgroups

3.3.1 Sex

A greater proportion of women than men reported gastrointestinal AEs in both the pooled analysis (P < .05 for exenatide once weekly; P < .001 for exenatide twice daily) and DURATION-6 (P < .01 for exenatide once weekly; P < .01 for liraglutide; Table 2).

3.3.2 Race/ethnicity

There were differences in the proportion of patients reporting gastrointestinal AEs when categorized by race/ethnicity in both analyses, but the direction of the difference was inconclusive (Table 2). In the pooled analysis, the proportion of patients with gastrointestinal AEs in the exenatide once-weekly group was lower for Asian and Hispanic patients than for white patients (both P < .001), without any difference for exenatide twice-daily-treated patients. In DURATION-6, the proportion of patients with gastrointestinal AEs was higher for Asian than for white patients with both exenatide once weekly (P < .05) and liraglutide (P < .01), with no differences between Hispanic and white patients.

3.3.3 Background metformin use

Continued use of metformin was not associated with increased gastrointestinal AEs in the pooled population (Table 2).

3.4 Timing of gastrointestinal AEs

Nausea was the most common gastrointestinal AE throughout the treatment period but differed between the GLP-1RAs. For exenatide once weekly, few patients reported nausea during each 2-week interval, and the proportion was consistently lower than with exenatide twice daily or liraglutide (Figure 1C and D). With exenatide twice daily, nausea incidence peaked at weeks 4 to 6 and declined thereafter; for liraglutide, the proportion of patients reporting nausea was highest during the first 4 weeks, before decreasing.

The proportions of patients reporting vomiting, diarrhoea and constipation during any 2-week interval were <7%, <9% and <5%, respectively, for all treatments.

Vomiting remained infrequent throughout treatment with exenatide once weekly in the pooled analysis, while there was a peak at weeks 4 to 6 for exenatide twice daily. Similarly in DURATION-6, vomiting remained uncommon for exenatide once weekly throughout, but peaked during weeks 0 to 4 for liraglutide.

Diarrhoea was more frequent with exenatide once weekly (peaking at weeks 2–4) than with exenatide twice daily (peaking at weeks 2 and 4).
| TABLE 2  | Incidences of specific lower gastrointestinal AEs in patients treated with GLP-1RAs, and comparisons of gastrointestinal AEs between patient subgroups |
|----------|-------------------------------------------------------------------------------------------------------------------------------------|
| **Pooled analysis** | **Exenatide once weekly (n = 617)** | **Exenatide twice daily (n = 606)** | **DURATION-6** |
| **Subset of lower gastrointestinal AEs, n (%)** | | | **Exenatide once weekly (n = 461)** | **Liraglutide (n = 450)** |
| Total | 98 (15.9) | 86 (14.2) | 50 (10.8) | 84 (18.7)‡ |
| Diarrhoea + constipation | 7 (1.1) | 4 (0.7) | 3 (0.7) | 3 (0.7) |
| Diarrhoea only | 62 (10.0) | 47 (7.8) | 28 (6.1) | 61 (13.6)* |
| Constipation only | 29 (4.7) | 35 (5.8) | 19 (4.1) | 20 (4.4) |
| **Sex: women/men, n (%)** | | | | |
| N (women/men) | 275/342 | 280/326 | 207/254 | 205/245 |
| Total | | | | |
| Women | 106 (38.5)‡ | 157 (56.1)* | 66 (31.9)† | 99 (48.3)† |
| Men | 103 (30.1) | 118 (36.2) | 50 (19.7) | 87 (35.5) |
| **Upper + lower** | | | | |
| Women | 34 (12.4) | 37 (13.2) | 16 (7.7) | 34 (16.6) |
| Men | 27 (7.9) | 27 (8.3) | 14 (5.5) | 28 (11.4) |
| **Upper only** | | | | |
| Women | 46 (16.7) | 101 (36.1)* | 31 (15.0)‡ | 49 (23.9)‡ |
| Men | 44 (12.9) | 62 (19.0) | 19 (7.5) | 37 (15.1) |
| **Lower only** | | | | |
| Women | 26 (9.5) | 19 (6.8) | 19 (9.2) | 16 (7.8) |
| Men | 32 (9.4) | 29 (8.9) | 17 (6.7) | 22 (9.0) |
| **Race/ethnicity: Asian/Hispanic/white, n (%)** | | | | |
| N (Asian/Hispanic/white) | 345/53/204 | 344/61/173 | 55/98/304 | 56/99/287 |
| Total | | | | |
| Asian | 102 (29.6)* | 154 (44.8) | 21 (38.2)‡ | 33 (58.9)† |
| Hispanic | 9 (17.0)* | 22 (36.1) | 24 (45.5) | 36 (36.4) |
| White | 93 (45.6) | 88 (50.9) | 69 (22.7) | 113 (39.4) |
| **Upper + lower** | | | | |
| Asian | 29 (8.4)‡ | 35 (10.2) | 8 (14.5)‡ | 12 (21.4) |
| Hispanic | 1 (1.9)* | 2 (3.3)‡ | 7 (7.1) | 14 (14.1) |
| White | 29 (14.2) | 24 (13.9) | 15 (4.9) | 34 (11.8) |
| **Upper only** | | | | |
| Asian | 41 (11.9)† | 87 (25.3) | 7 (12.7) | 13 (23.2) |
| Hispanic | 4 (7.5)‡ | 16 (26.2) | 9 (9.2) | 15 (15.2) |
| White | 42 (20.6) | 54 (31.2) | 34 (11.2) | 58 (20.2) |
| **Lower only** | | | | |
| Asian | 32 (9.3) | 32 (9.3) | 6 (10.9) | 8 (14.3) |
| Hispanic | 4 (7.5) | 4 (6.6) | 8 (8.2) | 7 (7.1) |
| White | 22 (10.8) | 10 (5.8) | 20 (6.6) | 21 (7.3) |
| **Background metformin: use/non-use, n (%)** | | | | |
| N (metformin/no metformin) | 506/111 | 484/122 | | |
| Total | | | | |
| Metformin | 166 (32.8) | 225 (46.5) | | |
| No metformin | 43 (38.7) | 50 (41.0) | | |
| **Upper + lower** | | | | |
| Metformin | 48 (9.5) | 55 (11.4) | | |
| No metformin | 13 (11.7) | 9 (7.4) | | |
| **Upper only** | | | | |
| Metformin | 68 (13.4) | 135 (27.9) | | |
| No metformin | 22 (19.8) | 28 (23.0) | | |
TABLE 2 Continued

|                   | Pooled analysis                  | Exenatide twice daily (n = 606) | Exenatide once weekly (n = 617) | DURATION-6             |
|-------------------|----------------------------------|---------------------------------|---------------------------------|------------------------|
|                   |                                  |                                 |                                 | Exenatide once weekly  |
| Lower only        |                                  |                                 |                                 | weekly (n = 461)       |
| Metformin         | 50 (9.9)                         | 35 (7.2)                        |                                 | Liraglutide (n = 450)  |
| No metformin      | 8 (7.2)                          | 13 (10.7)                       |                                 |                        |

*P < .001. †P < .01. ‡P < .05.
† Statistical comparisons for subgroups are within each treatment group.
‡ White subgroup used as reference for comparisons.
§ Metformin alone or in combination with other oral glucose-lowering drugs or insulin.

4–6) and declined thereafter for each (Figure 1E). In DURATION-6, diarrhoea was more frequent with liraglutide (peaking at weeks 0–4) than with exenatide once weekly (Figure 1F). The proportion of patients reporting constipation remained low throughout treatment in all groups.

The first gastrointestinal AE of any kind occurred most frequently during the first 5 days for all treatments, with another peak between days 25 and 30 for exenatide twice daily. Few first events occurred after 3 months.

During the first 5 days of treatment, there were 40 first gastrointestinal AEs with exenatide once weekly, compared with 93 with exenatide twice daily. First events occurred in 20 exenatide once-weekly-treated patients, compared with 65 liraglutide-treated patients (Figure 2A and B). First events were more frequently upper than lower gastrointestinal AEs. Among patients who reported both upper gastrointestinal AEs and diarrhoea, these events generally occurred within 10 days of each other (Figure 2C and D).

3.5 | Severity, serious events and events leading to withdrawal

Gastrointestinal AEs were predominantly mild (74.8% for exenatide once weekly and 75.5% for exenatide twice daily; 83.0% for exenatide once weekly and 74.3% for liraglutide).

In the pooled analysis, mild, moderate and severe gastrointestinal AEs were reported by 30.3%, 9.7% and 1.3% of exenatide once-weekly-treated patients and by 38.6%, 12.4% and 1.7% of exenatide twice-daily-treated patients, respectively. In DURATION-6, the corresponding proportions were 23.0%, 4.8% and 1.3% for exenatide once weekly and 34.2%, 12.9% and 2.9% for liraglutide.

Few serious gastrointestinal AEs were reported for any of the GLP-1RAs (four with exenatide once weekly and two with exenatide twice daily in the pooled analysis; three with exenatide once weekly and three with liraglutide in DURATION-6 [Table S5, Supporting Information]).

Discontinuation because of gastrointestinal AEs was infrequent and occurred less with exenatide once weekly vs exenatide twice daily (1% vs 6% of patients; P < .0001) and exenatide once weekly vs liraglutide (1% vs 4% of patients; P < .05). Nausea and vomiting were the gastrointestinal AEs that most often led to withdrawal of exenatide twice daily and liraglutide; no trend was apparent for exenatide once weekly (Table S6, Supporting Information). In the exenatide twice-daily and liraglutide groups, nausea events that led to withdrawal mainly occurred within the first month of treatment.

3.6 | Association between gastrointestinal AEs and treatment effects

Reductions from baseline in HbA1c and body weight occurred with all treatments at week 26 (all P < .05 vs baseline). The reduction in HbA1c did not differ between patients with upper and/or lower gastrointestinal AEs and those without in any analysis (Figure 2E). Weight loss was greater in patients who reported gastrointestinal AEs than in those who did not in the exenatide once-weekly (−2.7 kg vs −2.0 kg; P < .05) and exenatide twice-daily groups (−2.8 kg vs −2.0 kg; P < .05) in the pooled analysis (Figure 2F). There were no differences in weight loss for exenatide once weekly or liraglutide in DURATION-6 (Figure 2F).

4 | DISCUSSION

Gastrointestinal symptoms occur frequently in patients with T2D and represent a substantial cause of morbidity, so it is important to understand the potential effects of medications on these symptoms. GLP-1RAs have been shown to reduce HbA1c and body weight, with low intrinsic risk of hypoglycaemia. One potential AE associated with these agents is an increase in gastrointestinal events that is transient in most cases. As such, understanding the specific gastrointestinal AE profile and how it varies across the GLP-1RA class is of interest for patients and physicians, and may be useful in guiding therapy.

Both pooled patient-level data and a single trial were studied in the present analysis, so that data for three separate GLP-1RAs were available. The most common gastrointestinal AEs reported were nausea, vomiting and diarrhoea. Other diagnoses, including dyspepsia and gastroesophageal reflux disease, were also associated with the GLP-1RAs studied, but differed between individual GLP-1RAs and were reported less frequently (Table S4, Supporting Information). The results also suggest that some patients experience both upper and lower gastrointestinal AEs, most commonly nausea followed within 10 days by diarrhoea—an observation not, to our knowledge, previously reported.

Incidence of gastrointestinal AEs differed between the GLP-1RAs investigated. Upper gastrointestinal AEs were less common for exenatide once weekly, compared with exenatide twice daily and...
liraglutide. In contrast, the frequency of lower gastrointestinal AEs was similar across treatment groups, although diarrhoea occurred more frequently with liraglutide than with exenatide once weekly. Constipation was uncommon, and most patients reporting constipation also reported diarrhoea at a different time during treatment. While constipation has been reported by patients treated with GLP-1RAs, its incidence in clinical trials has varied considerably between agents. Patients who reported both upper and lower gastrointestinal AEs were more commonly treated with liraglutide than with exenatide once weekly; however, there was no significant difference.
between exenatide once weekly and exenatide twice daily. It is likely that a similar analysis with other GLP-1RAs would also show differences in the incidence of gastrointestinal AEs. In head-to-head studies, albiglutide was associated with lower rates of nausea and vomiting compared with liraglutide,17 while gastrointestinal AE rates were similar for dulaglutide 1.5 mg vs exenatide twice daily or liraglutide and lower for dulaglutide 0.75 mg vs exenatide twice daily.18,19

Several studies have suggested a possible relationship between gastrointestinal symptoms and HbA1c in patients with T2D,10,20–22 with symptoms occurring more frequently in patients with poor glycaemic control and higher HbA1c levels, possibly because of the impact of long-term poor glycaemic control on diabetic complications, such as autonomic neuropathy; however, this association was not observed in the present analyses. Additionally, the presence of...
gastrointestinal AEs as a whole did not influence changes in HbA1c in response to therapy; however, in the pooled analysis, patients who reported gastrointestinal AEs had significantly greater weight loss than those who did not in both the exenatide once-weekly and exenatide twice-daily groups, although absolute differences in mean weight loss were <1 kg. This is consistent with the outcome of a recent analysis of 12 studies that found that weight loss among exenatide once-weekly-treated patients was greater for those with nausea/vomiting at 24 weeks than those without (−3.1 kg vs −2.2 kg; P < .05).23

Although it is commonly perceived that GLP-1RAs cause gastrointestinal AEs by slowing gastric emptying, there is, in general, a weak relationship of symptoms with delayed gastric emptying.24 Moreover, symptoms occur in the fasted state;25 therefore, it is likely that centrally mediated effects are important. While the effects of GLP-1RAs on regions of the gut other than the stomach have not been extensively studied, the potential for exenatide twice daily to inhibit small intestinal motor function was recently demonstrated,3 and such effects may contribute to lower gastrointestinal symptoms such as diarrhea or constipation.

Possible reasons for differences in gastrointestinal AEs between GLP-1RAs include differences in drug concentration profiles; the half-life and time to minimal effective and steady-state concentrations are much longer for exenatide once weekly than for exenatide twice daily or liraglutide.11,26,27 GLP-1RAs also differ in their ability to cross the blood–brain barrier, with small-molecule GLP-1RAs such as exenatide, liraglutide and lixisenatide being able to enter the brain, whereas larger GLP-1RAs such as albglutide cannot;27–29 it is possible that these differences impact centrally mediated AEs. It was recently established that tachyphylaxis occurs for the effects of exogenous glucagon-like peptide-1 on the slowing of gastric emptying with prolonged exposure.30 Thus, while short-acting GLP-1RAs such as exenatide twice daily are likely to have a sustained effect to slow gastric emptying substantially, this effect is likely to be markedly diminished with longer-acting formulations such as exenatide once weekly or liraglutide.2,26 It is unknown whether a similar phenomenon applies to the effects of GLP-1RAs on other gut regions (eg, the small or large intestine), or for the central effects of these agents.

In the present analysis we also examined whether any patient characteristics influenced the gastrointestinal effects of GLP-1RAs. For all treatments, upper gastrointestinal AEs were reported more frequently by women than men; this is consistent with pooled analyses of 7 studies of exenatide once weekly21 and 16 studies involving exenatide twice daily.22 Even aside from drug studies, gastrointestinal symptoms are consistently reported more frequently in women than men, with or without diabetes,10 for reasons that are not well understood.

When analysed by race/ethnicity, there were inconsistent outcomes for comparisons of exenatide once weekly vs exenatide twice daily and exenatide once weekly vs liraglutide. This suggests that race/ethnicity has little, if any, effect on the occurrence of gastrointestinal AEs and is consistent with previous pooled analyses of 7 exenatide once-weekly studies21 and 16 exenatide twice-daily studies.22 Finally, metformin use had no significant effect on the proportion of patients experiencing gastrointestinal AEs. This contrasts with a previous study indicating a strong association of diarrhoea and faecal incontinence with metformin use in T2D.23 Given that metformin use was stable before study entry, it is possible that individuals who had AEs from metformin were not represented in the study populations.

Limitations inherent in post hoc analyses include their retrospective nature and the potential for selection bias resulting from differences between patients eligible for clinical trials and those seen in clinical practice. Furthermore, we focused on three specific GLP-1RAs evaluated in the exenatide once-weekly development programme, rather than the class as a whole, and the studies were not placebo-controlled (ie, the lack of a placebo group made it difficult to determine how many gastrointestinal AEs were unrelated to study medication); moreover, patient histories of gastrointestinal disorders before study entry were not systematically recorded. Recording of gastrointestinal AEs was based on patient reports, which are likely to represent an underestimate of the true incidences.34 Furthermore, gastrointestinal AE data were not adjudicated, study investigators were not instructed in common gastrointestinal terminology, patients did not use a rating scale for severity of symptoms, and the timing and duration of events were not recorded precisely. Nevertheless, the proportions of patients reporting gastrointestinal AEs are in line with previous studies involving GLP-1RAs.5

In conclusion, the present study provides detailed information on the gastrointestinal tolerability of three GLP-1RAs based on patient-level data from the exenatide once-weekly clinical trial programme. Gastrointestinal AEs were usually mild and transient and particularly affected the upper gastrointestinal tract, and occurred more frequently with exenatide twice daily and liraglutide than with exenatide once weekly. These insights inform physician and patient expectations of potential experiences when initiating GLP-1RA therapy.

ACKNOWLEDGMENTS

Raewyn Poole and Mollie Marko of inScience Communications, Springer Healthcare, provided medical writing support funded by AstraZeneca. The manuscript was reviewed by Mary Beth DeYoung of AstraZeneca LP.

Conflict of interest

M. H. has participated in advisory boards and/or symposia for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk and Sanofi and has received honoraria for this activity. V. R. A. has received research funding from AstraZeneca/Bristol-Myers Squibb, Calibra, Eisai, Elcelyx, Janssen, Novo Nordisk, Sanofi and Theracos, and has performed consulting activities for Adocia, the American Diabetes Association, AstraZeneca, Janssen, Medscape, Novo Nordisk, Sanofi and Tufts. J. H. has received payment for consulting work from AstraZeneca. E. H. is an employee and stockholder of AstraZeneca. C. K. R. has received research funding from AstraZeneca, Merck Sharp & Dohme, Novartis, and Sanofi.
Author contributions

M. H., V. R. A., J. H., E. H. and C. K. R. conceived the analysis and participated in the writing of the manuscript. All authors approved the final version of the manuscript.

REFERENCES

1. Sun F, Chai S, Yu K, et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Technol Ther. 2015;17:35-42.

2. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117:77-88.

3. Thazhath SS, Marathe CS, Wu T, et al. The glucagon-like peptide 1 receptor agonist exenatide inhibits small intestinal motility, flow, transit, and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomized controlled trial. Diabetes. 2016;65:269-275.

4. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240-1245.

5. Meier JJ, Rosenstock J, Hincelin-Mery A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomised, open-label trial. Diabetes Care. 2015;38:1263-1273.

6. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.

7. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:1301-1310.

8. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381:117-124.

9. Ji L, Onishi Y, Ahn CW, et al. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. J Diabetes Invest. 2013;4:53-61.

10. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001;161:1989-1996.

11. BYETTA (exenatide) injection [package insert]. Wilmington, DE: AstraZeneca; 2015.

12. VICTOZA (liraglutide) injection, for subcutaneous use [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2016.

13. BYDUREON (exenatide extended release) for injectable suspension [package insert]. Wilmington, DE: AstraZeneca; 2015.

14. TANZEUM (albiglutide) for injection, for subcutaneous use [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2015.

15. TRULICITY (dulaglutide) injection [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015.

16. Lyxumia (lixisenatide) summary of product characteristics. Paris, France: Sanofi-Aventis Groupe; 2013.

17. Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289-297.

18. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384:1349-1357.

19. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37:2159-2167.

20. Abid S, Rizvi A, Jahan F, et al. Poor glycaemic control is the major factor associated with increased frequency of gastrointestinal symptoms in patients with diabetes mellitus. J Pak Med Assoc. 2007;57:345-349.

21. Bytzer P, Talley NJ, Hammer J, Young LJ, Jones MP, Horowitz M. GI symptoms in diabetes mellitus are associated with both poor glyemic control and diabetic complications. Am J Gastroenterol. 2002;97:604-611.

22. Kim JH, Park HS, Ko SY, et al. Diabetic factors associated with gastrointestinal symptoms in patients with type 2 diabetes. World J Gastroenterol. 2010;16:1782-1787.

23. Trautmann ME, Han J, Ruggles J. Early pharmacodynamic effects of exenatide once weekly in type 2 diabetes are independent of weight loss: a pooled analysis of patient-level data. Clin Ther. 2016;38:1464-1473.

24. Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care. 2001;24:1264-1269.

25. Nauck MA, Wollschlag D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 [GLP-1 (7-36 amide)] in patients with NIDDM. Diabetologia. 1996;39:1546-1553.

26. Fineman M, Flanagan S, Taylor K, et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet. 2011;50:65-74.

27. Gerich J. Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. Int J Gen Med. 2013;6:877-895.

28. Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33.

29. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord. 2003;27:313-318.

30. Umapathysivam MM, Lee MY, Jones KL, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014;63:785-790.

31. Pencek R, Blickensderfer A, Li Y, Brunell SC, Chen S. Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations. Int J Clin Pract. 2012;66:1021-1032.

32. Pencek R, Blickensderfer A, Li Y, Brunell SC, Anderson PW. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med. 2012;124:21-32.

33. Bytzer P, Talley NJ, Jones MP, Horowitz M. Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. Aliment Pharmacol Ther. 2001;15:137-142.

34. Molinder H, Agreus L, Kjellstrom L, et al. How individuals with the irritable bowel syndrome describe their own symptoms before formal diagnosis. Ups J Med Sci. 2015;120:276-279.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Horowitz M, Aroda VR, Han J, Hardy E and Rayner CK. Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences. Diabetes Obes Metab. 2017;19:672–681. https://doi.org/10.1111/dom.12872